Related references
Note: Only part of the references are listed.Resistance Mutations Against HCV Protease Inhibitors and Antiviral Drug Design
Luqing Shang et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease
Yutong Jiang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
Paul M. Scola et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Negative selection and stringency modulation in phage-assisted continuous evolution
Jacob C. Carlson et al.
NATURE CHEMICAL BIOLOGY (2014)
A Population-Based Experimental Model for Protein Evolution: Effects of Mutation Rate and Selection Stringency on Evolutionary Outcomes
Aaron M. Leconte et al.
BIOCHEMISTRY (2013)
Resistance Analysis of Hepatitis C Virus Genotype 1 Prior Treatment Null Responders Receiving Daclatasvir and Asunaprevir
Fiona McPhee et al.
HEPATOLOGY (2013)
New therapeutic strategies in HCV: second-generation protease inhibitors
Virginia C. Clark et al.
LIVER INTERNATIONAL (2013)
Novel therapies for hepatitis C - one pill fits all?
Michael P. Manns et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Experimental interrogation of the path dependence and stochasticity of protein evolution using phage-assisted continuous evolution
Bryan C. Dickinson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Engineering of TEV protease variants by yeast ER sequestration screening (YESS) of combinatorial libraries
Li Yi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Virologic Escape during Danoprevir (ITMN-191/RG7227) Monotherapy Is Hepatitis C Virus Subtype Dependent and Associated with R155K Substitution
Sharlene R. Lim et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir
Fiona McPhee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
Keith P. Romano et al.
PLOS PATHOGENS (2012)
Proteases as therapeutics
Charles S. Craik et al.
BIOCHEMICAL JOURNAL (2011)
Genotype Differences in Susceptibility and Resistance Development of Hepatitis C Virus to Protease Inhibitors Telaprevir (VX-950) and Danoprevir (ITMN-191)
Ingrid Imhof et al.
HEPATOLOGY (2011)
A system for the continuous directed evolution of biomolecules
Kevin M. Esvelt et al.
NATURE (2011)
Activation of Specific Apoptotic Caspases with an Engineered Small-Molecule-Activated Protease
Daniel C. Gray et al.
CELL (2010)
Design of next-generation protein therapeutics
Justin Caravella et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Tracking the Evolution of Multiple In Vitro Hepatitis C Virus Replicon Variants under Protease Inhibitor Selection Pressure by 454 Deep Sequencing
Thierry Verbinnen et al.
JOURNAL OF VIROLOGY (2010)
Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding
Keith P. Romano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
Libin Rong et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Engineering of protease variants exhibiting altered substrate specificity
Saravanan Sellamuthu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites
Oliver Schilling et al.
NATURE BIOTECHNOLOGY (2008)
Highly active and selective endopeptidases with programmed substrate specificities
Navin Varadarajan et al.
NATURE CHEMICAL BIOLOGY (2008)
A remodelled protease that cleaves phosphotyrosine substrates
Zachary A. Knigh et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2007)
Monitoring regulated protein-protein interactions using split TEV
Michael C. Wehr et al.
NATURE METHODS (2006)
Rep and PriA helicase activities prevent RecA from provoking unnecessary recombination during replication fork repair
Akeel A. Mahdi et al.
GENES & DEVELOPMENT (2006)
Biopharmaceutical benchmarks 2006
Gary Walsh
NATURE BIOTECHNOLOGY (2006)
Targeting proteases: successes, failures and future prospects
Boris Turk
NATURE REVIEWS DRUG DISCOVERY (2006)
Engineering of protease variants exhibiting high catalytic activity and exquisite substrate selectivity
N Varadarajan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Identification of mutator genes and mutational pathways in Escherichia coli using a multicopy cloning approach
HJ Yang et al.
MOLECULAR MICROBIOLOGY (2004)
Immunotherapy: past, present and future
TA Waldmann
NATURE MEDICINE (2003)
Tobacco etch virus protease:: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency
RB Kapust et al.
PROTEIN ENGINEERING (2001)
Predicting the emergence of antibiotic resistance by directed evolution and structural analysis
MC Orencia et al.
NATURE STRUCTURAL BIOLOGY (2001)
Share Paper
